Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease

FASEB Journal

Volumn 27, Issue 1, 2013, Pages 34-44

  Li, Songtao ^a   Sun, Baodong ^a   Nilsson, Mats I ^b   Bird, Andrew ^a   Tarnopolsky, Mark A ^b   Thurberg, Beth L ^c   Bali, Deeksha ^a   Koeberl, Dwight D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^c GENZYME CORPORATION   (United States)

Author keywords

Acid glucosidase; Acid maltase; Adeno associated virus; Gene therapy; Glycogen storage disease type II; Mannose 6 phosphate receptor

Indexed keywords

CLENBUTEROL; GLYCOGEN; PARVOVIRUS VECTOR; SALBUTAMOL; SOMATOMEDIN B RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EXTENSOR DIGITORUM LONGUS MUSCLE; GENE REPLACEMENT THERAPY; GLYCOGEN STORAGE DISEASE TYPE 2; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; SOLEUS MUSCLE; TIBIALIS ANTERIOR MUSCLE; UPREGULATION;

ADRENERGIC BETA-AGONISTS; ALPHA-GLUCOSIDASES; ANIMALS; COMBINED MODALITY THERAPY; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; GLYCOGEN STORAGE DISEASE TYPE II; MICE; MICE, KNOCKOUT; NEUROMUSCULAR JUNCTION; RECEPTORS, ADRENERGIC, BETA-2;

ADENO-ASSOCIATED VIRUS; MURINAE; MUS;

EID: 84871896151     PISSN: None     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.12-207472     Document Type: Article

References (56)

1. Desnick, R. J. (2004) Enzyme replacement and enhancement therapies for lysosomal diseases. J. Inher. Met. Dis. 27, 385-410
2. Raben, N., Fukuda, T., Gilbert, A. L., De Jong, D.,Thurberg, B. L., Mattaliano, R. J., Meikle, P., Hopwood, J. J., Nagashima, K., Nagaraju, K., and Plotz, P. H. (2005) Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol. Ther. 11, 48-56 (Pubitemid 40011998)
3. Koeberl, D. D. Luo, X., Sun, B., McVie-Wylie, A., Dai, J., Li, S., Banugaria, S. G., Chen, Y. T., and Bali, D. S. (2011) Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol. Genet. Metab. 103, 107-112
4. Cardone, M., Porto, C., Tarallo, A., Vicinanza, M., Rossi, B., Polishchuk, E., Donaudy, F., Andria, G., De Matteis, M. A., and Parenti, G. (2008) Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. Pathogenetics 1, 6
5. Zhu, Y., Li, X., McVie-Wylie, A., Jiang, C., Thurberg, B. L., Raben, N., Mattaliano, R. J., and Cheng, S. H. (2005) Carbohy-drate-remodeled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Neuromusc. Dis. 15, 712-713
6. McVie-Wylie, A. J., Lee, K. L., Qiu, H., Jin, X., Do, H., Gotschall, R., Thurberg, B. L., Rogers, C., Raben, N., O'Callaghan, M., Canfield, W., Andrews, L., McPherson, J. M., and Mattaliano, R. J. (2008) Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol. Genet. Metab. 94, 448-455
7. Zhu, Y., Jiang, J. L., Gumlaw, N. K., Zhang, J., Bercury, S. D., Ziegler, R. J., Lee, K., Kudo, M., Canfield, W. M., Edmunds, T., Jiang, C., Mattaliano, R. J., and Cheng, S. H. (2009) Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol. Ther. 17, 954-963
8. Kobayashi, H., Shimada, Y., Ikegami, M., Kawai, T., Sakurai, K., Urashima, T., Ijima, M., Fujiwara, M., Kaneshiro, E., Ohashi, T., Eto, Y., Ishigaki, K., Osawa, M., Kyosen, S. O., and Ida, H. (2010) Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case. Mol. Genet. Metab. 100, 14-19
9. Strothotte, S., Strigl-Pill, N., Grunert, B., Kornblum, C., Eger, K., Wessig, C., Deschauer, M., Breunig, F., Glocker, F. X., Vielhaber, S., Brejova, A., Hilz, M., Reiners, K., Muller-Felber, W., Mengel, E., Spranger, M., and Schoser, B. (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J. Neurol. 257, 91-97
10. Kishnani, P. S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W. L., Leslie, N., Levine, J., Spencer, C., McDonald, M., Li, J., Dumontier, J., Halberthal, M., Chien, Y. H., Hopkin, R., Vijayaraghavan, S., Gruskin, D., Bartholomew, D., Van Der, P. A., Clancy, J. P., Parini, R., Morin, G., Beck, M., De La Gastine, G. S., Jokic, M., Thurberg, B., Richards, S., Bali, D., Davison, M., Worden, M. A., Chen, Y. T., and Wraith, J. E. (2007) Recombinant human acid alpha-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68, 99-109 (Pubitemid 46071892)
11. Nicolino, M., Byrne, B., Wraith, J. E., Leslie, N., Mandel, H., Freyer, D. R., Arnold, G. L., Pivnick, E. K., Ottinger, C. J., Robinson, P. H., Loo, J. C., Smitka, M., Jardine, P., Tato, L., Chabrol, B., McCandless, S., Kimura, S., Mehta, L., Bali, D., Skrinar, A., Morgan, C., Rangachari, L., Corzo, D., and Kishnani, P. S. (2009) Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet. Med. 11, 210-219
12. Jones, P. S., Muller, C. W., Lin, M., Banugaria, S. G., Case, L. E., Li, J. S. O'Grady, G., Heller, J. H., and Kishnani, P. S. (2009) Oropharyngeal dysphagia in infants and children with infantile Pompe disease. Dysphagia 25, 277-283
13. Yanovitch, T. L., Banugaria, S. G., Proia, A. D., and Kishnani, P. S. (2010) Clinical and histologic ocular findings in Pompe disease. J. Pediatr. Ophthalmol. Strabismus 47, 34-40
14. Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., and Wilson, J. M. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99, 11854-11859 (Pubitemid 34994488)
15. Sun, B., Zhang, H., Franco, L. M., Young, S. P., Schneider, A., Bird, A., Amalfitano, A., Chen, Y. T., and Koeberl, D. D. (2005) Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol. Ther. 11, 57-65 (Pubitemid 40011999)
16. Franco, L. M., Sun, B., Yang, X., Bird, A., Zhang, H., Schneider, A., Brown, T., Young, S. P., Clay, T. M., Amalfitano, A., Chen, Y. T., and Koeberl, D. D. (2005) Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol. Ther. 12, 876-884 (Pubitemid 41614483)
17. Sun, B., Kulis, M. D., Young, S. P., Hobeika, A. C., Li, S., Bird, A., Zhang, H., Li, Y., Clay, T. M., Burks, W., Kishnani, P. S., and Koeberl, D. D. (2010) Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease. Mol. Ther. 18, 353-360
18. Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Rustagi, P. K., Nakai, H., Chew, A., Leonard, D., Wright, J. F., Lessard, R. R., Sommer, J. M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Mingozzi, F., Couto, L., Ertl, H. C., High, K. A., and Kay, M. A. (2006) Successful transduction of liver in hemophilia by AAVFactor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347 (Pubitemid 43355084)
19. Wang, L., Figueredo, J., Calcedo, R., Lin, J., and Wilson, J. M. (2007) Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum. Gene Ther. 18, 185-194 (Pubitemid 46626458)
20. Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., Grant, R. L., Gao, G., and Wilson, J. M. (2006) Heparin binding directs activation of T cells against adenoassociated virus serotype 2 capsid. Nat. Med. 12, 967-971 (Pubitemid 44175151)
21. Koeberl, D. D., Pinto, C., Sun, B., Li, S., Kozink, D. M., Benjamin, D. K., Jr., Demaster, A. K., Kruse, M. A., Vaughn, V., Hillman, S., Bird, A., Jackson, M., Brown, T., Kishnani, P. S., and Chen, Y. T. (2008) AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia. Mol. Ther. 16, 665-672 (Pubitemid 351426167)
22. Amalfitano, A., McVie-Wylie, A. J., Hu, H., Dawson, T. L., Raben, N., Plotz, P., and Chen, Y. T. (1999) Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc. Natl. Acad. Sci. U. S. A. 96, 8861-8866 (Pubitemid 29374673)
23. Cresawn, K. O., Fraites, T. J., Wasserfall, C., Atkinson, M., Lewis, M., Porvasnik, S., Liu, C., Mah, C., and Byrne, B. J. (2005) Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II. Hum. Gene Ther. 16, 68-80 (Pubitemid 40250333)
24. Raben, N., Danon, M., Gilbert, A. L., Dwivedi, S., Collins, B., Thurberg, B. L., Mattaliano, R. J., Nagaraju, K., and Plotz, P. H. (2003) Enzyme replacement therapy in the mouse model of Pompe disease. Mol. Genet. Metab. 80, 159-169 (Pubitemid 37272242)
25. Matsumoto, T., Akutsu, S., Wakana, N., Morito, M., Shimada, A., and Yamane, A. (2006) The expressions of insulin-like growth factors, their receptors, and binding proteins are related to the mechanism regulating masseter muscle mass in the rat. Arch. Oral. Biol. 51, 603-611 (Pubitemid 43849639)
26. Sun, B., Zhang, H., Bird, A., Li, S., Young, S. P., and Koeberl, D. D. (2009) Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vectormediated transgene expression. J. Gene Med. 11, 913-920
27. Xu, F., Ding, E., Migone, F., Serra, D., Schneider, A., Chen, Y. T., and Amalfitano, A. (2005) Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA. J. Gene Med. 7, 171-178 (Pubitemid 40348021)
28. Wylie, A. A., Pulford, D. J., McVie-Wylie, A. J., Waterland, R. A., Evans, H. K., Chen, Y. T., Nolan, C. M., Orton, T. C., and Jirtle, R. L. (2003) Tissue-specific inactivation of murine M6P/IGF2R. Am. J. Pathol. 162, 321-328 (Pubitemid 36042014)
29. Taksir, T. V., Griffiths, D., Johnson, J., Ryan, S., Shihabuddin, L. S., and Thurberg, B. L. (2007) Optimized preservation of CNS morphology for the identification of glycogen in the Pompe mouse model. J. Histochem. Cytochem. 55, 991-998 (Pubitemid 47427646)
30. Sun, B., Li, S., Bird, A., Yi, H., Kemper, A., Thurberg, B. L., and Koeberl, D. D. (2010) Antibody formation and mannose-6- phosphate receptor expression impact the efficacy of musclespecific transgene expression in murine Pompe disease. J. Gene Med. 25, 277-283
31. Sun, B., Bird, A., Young, S. P., Kishnani, P. S., Chen, Y. T., and Koeberl, D. D. (2007) Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am. J. Hum. Genet. 81, 1042-1049 (Pubitemid 47580255)
32. Miura, S., Kawanaka, K., Kai, Y., Tamura, M., Goto, M., Shiuchi, T., Minokoshi, Y., and Ezaki, O. (2007) An increase in murine skeletal muscle peroxisome proliferator-activated receptorgamma coactivator-1alpha (PGC-1alpha) mRNA in response to exercise is mediated by beta-adrenergic receptor activation. Endocrinology 148, 3441-3448 (Pubitemid 46997005)
33. Mah, C. S., Falk, D. J., Germain, S. A., Kelley, J. S., Lewis, M. A., Cloutier, D. A., Deruisseau, L. R., Conlon, T. J., Cresawn, K. O., Fraites, T. J., Jr., Campbell-Thompson, M., Fuller, D. D., and Byrne, B. J. (2010) Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol. Ther. 18, 502-510
34. Lynch, G. S., and Ryall, J. G. (2008) Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol. Rev. 88, 729-767 (Pubitemid 351520091)
35. Sandri, M. (2008) Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 23, 160-170
36. Mounier, R., Cavalie, H., Lac, G., and Clottes, E. (2007) Molecular impact of clenbuterol and isometric strength training on rat EDL muscles. Pflügers Arch. 453, 497-507 (Pubitemid 46011170)
37. Maclennan, P. A., and Edwards, R. H. (1989) Effects of clenbuterol and propranolol on muscle mass. Evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce hypertrophy. Biochem. J. 264, 573-579
38. Awede, B. L., Thissen, J. P., and Lebacq, J. (2002) Role of IGF-I and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol. Am. J. Physiol. Endocrinol. Metab. 282, E31-E37 (Pubitemid 34654103)
39. Iizuka, H., Osaka, Y., Kondo, S., and Morita, T. (1998) Effect of an atypical adrenergic beta3-agonist, GS-332: sodium (2R)-[3-[3-[2-(3-chlorophenyl) -2-hydroxyethylamino]cyclohexyl]phenoxy] acetate, on urinary bladder function in rats. J. Smooth Muscle Res. 34, 139-149 (Pubitemid 29146858)
40. Torneke, K., Ingvast Larsson, C., and Appelgren, L. E. (1998) A comparison between clenbuterol, salbutamol and terbutaline in relation to receptor binding and in vitro relaxation of equine tracheal muscle. J. Vet. Pharmacol. Ther. 21, 388-392 (Pubitemid 28488104)
41. Nials, A. T., Coleman, R. A., Johnson, M., Magnussen, H., Rabe, K. F., and Vardey, C. J. (1993) Effects of beta-adrenoceptor agonists in human bronchial smooth muscle. Br. J. Pharmacol. 110, 1112-1116 (Pubitemid 24005248)
42. Zimmer, A. (1976) [Single and multiple applications and metabolite pattern of clenbuterol in man (author's transl.)]. Arzneimittelforschung 26, 1446-1450
43. Kissel, J. T., McDermott, M. P., Mendell, J. R., King, W. M., Pandya, S., Griggs, R. C., and R. Tawil. (2001) Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology 57, 1434-1440 (Pubitemid 32995725)
44. Fowler, E. G., Graves, M. C., Wetzel, G. T., and Spencer, M. J. (2004) Pilot trial of albuterol in Duchenne and Becker muscular dystrophy. Neurology 62, 1006-1008 (Pubitemid 38435800)
45. Skura, C. L., Fowler, E. G., Wetzel, G. T., Graves, M., and Spencer, M. J. (2008) Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology 70, 137-143
46. Kamalakkannan, G., Petrilli, C. M., George, I., LaManca, J., McLaughlin, B. T., Shane, E., Mancini, D. M., and Maybaum, S. (2008) Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. J. Heart Lung Transplant. 27, 457-461 (Pubitemid 351418249)
47. Soraru, G., Pegoraro, E., Spinella, P., Turra, S., D'ascenzo, C., Baggio, L., Mantovan, M. C., Vergani, L., and Angelini, C. (2006) A pilot trial with clenbuterol in amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler. 7, 246-248
48. Angelini, E. P. C., Marsala, S. Z., Vergani, L., Nascimbeni, A. C., Fulizio, L., and Fanin, M. (2004) Adult acid maltase deficiency: an open trial with albuterol and branched-chain aminoacids. Basic Appl. Myol. 14, 71-78
49. Grubb, J. H., Vogler, C., and Sly, W. S. (2010) New strategies for enzyme replacement therapy for lysosomal storage diseases. Rejuvenation Res. 13, 229-236
50. Uc, E. Y., Dienel, G. A., Cruz, N. F., and Harik, S. I. (2002) Beta-adrenergics enhance brain extraction of levodopa. Mov. Disord. 17, 54-59 (Pubitemid 36041260)
51. Koeberl, D. D., Li, S., Dai, J., Thurberg, B. L., Bali, D., and Kishnani, P. S. (2012) Beta2 agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol. Genet. Metab. 105, 221-227
52. Matthes, F., Wolte, P., Bockenhoff, A., Huwel, S., Schulz, M., Hyden, P., Fogh, J., Gieselmann, V., Galla, H. J., and Matzner, U. (2011) Transport of arylsulfatase A across the blood-brain barrier in vitro. J. Biol. Chem. 286, 17487-17494
53. Wraith, J. E., Scarpa, M., Beck, M., Bodamer, O. A., De Meirleir, L., Guffon, N., Meldgaard Lund, A., Malm, G., Van Der Ploeg, A. T., and Zeman, J. (2008) Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur. J. Pediatr. 167, 267-277
54. Ryall, J. G., and Lynch, G. S. (2008) The potential and the pitfalls of beta-2-adrenoceptor agonists for the management of skeletal muscle wasting. Pharmacol. Amp. Ther. 120, 219-232
55. Hoshino, D., Yoshida, Y., Holloway, G. P., Lally, J., Hatta, H., and Bonen, A. (2012) Clenbuterol, a beta-2-adrenergic agonist, reciprocally alters PGC-1 alpha and RIP140 and reduces fatty acid and pyruvate oxidation in rat muscle. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R373-R384
56. Scaglia, F., Towbin, J. A., Craigen, W. J., Belmont, J. W., Smith, E. O., Neish, S. R., Ware, S. M., Hunter, J. V., Fernbach, S. D., Vladutiu, G. D., Wong, L. J., and Vogel, H. (2004) Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease. Pediatrics 114, 925-931 (Pubitemid 41529754)